CoChat

The Future of Continuous Glucose Monitoring

Open access
Garg, Satish K., Akturk, Halis K. · 2017 · Diabetes Technology & Therapeutics
Cited by 34

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

More than three decades ago, when self-monitoring of blood glucose (SMBG) was first made available, most people doubted its uptake by questioning ‘‘who, why, and when?’’ Debates were around about why patients would poke their fingers few times a day and moreover, what will they do with the data? Today, it is the standard of care and was successfully used in the Diabetes Complications and Control Trial especially in the intensive arm. Most of the recent data from the type 1 diabetes (T1D) Exchange show increased SMBG monitoring results in better reduction of A1c in patients with T1D. Similar criticism surrounds continuous glucose monitoring (CGM) now. The first available retrospective CGM system was MiniMed iPro (nearly two decades ago) followed by the real-time display GlucoWatch in the year 2000 for 12 h using reversed iontophoresis. The next decade saw significant advances in CGM technologies by the Navigator (Abbott), Dexcom short-term sensor (STS), Gen 4 and 5 , and Medtronic Enlite and Guardian 3 . Most of the advances focused on improved accuracy where single digit mean absolute relative difference has become the standard, and in many instances, CGMs are now as accurate as SMBG. The early adoption of CGM was slow as expected with any new technology innovation. More recent data show a rapid increase in adoption rate across the United States and Western Europe, in part, due to improved accuracy and better coverage by the payers. As the number of patients using CGM increases, one hopes that the cost will go down. In this supplement, Graham discussed the challenges in the global reimbursement of CGM. In the future, CGM data will be available (currently only Dexcom Gen 5 ) on all mobile phones that use Bluetooth and insulin pumps without needing the data going through a receiver. Also, further advances in the technology will allow CGM to be used for 14 days without any calibration (factory calibration) or any need for an additional transmitter or receiver. After the 14-day use, the subject discards the whole CGM unit. As described by Hughes et al. in this supplement, once-daily calibrated real-time CGMs that have 10-day functional life may become available shortly. Currently, only FreeStyle Professional Libre (factory calibrated), flash glucose monitoring, is available in the US for 14 days for professional use. However, it is approved in Europe for personal use too. The flash glucose monitoring data are only available on demand and have no alarm feature. Please see the details of flash glucose monitoring in another supplement. It is also important to highlight that the future may see all CGM systems to be factory calibrated and data could be used to adjust insulin dose as a nonadjunctive device. Most patients do not use CGM as an adjunctive device to SMBG, and the Food and Drug Administration (FDA) recently approved Dexcom Gen 5 system data, which can be used as a nonadjunctive, except that it still needs calibration twice a day. Just like all patients with new-onset T1D get an SMBG meter today, we hope in the very near future, all patients with new-onset T1D will receive CGM. Forlenza et al. also emphasized challenges of the use of CGM in children and older adults in this supplement. The availability of CGMs has highlighted the deficiencies in following diabetes care based on A1c estimations. Glucose control measured by A1c values is a snapshot of overall glucose values for the past 1–3 months. It does not detect hypoglycemia or hyperglycemia on a day-to-day basis where patients need that information on a continual basis. The availability of CGM data has allowed patients and providers to not only improve glucose control but also reduce hypoglycemia and hyperglycemia across all ranges. This concept is further discussed in detail by Rodbard in this supplement. The CGM data can be summarized as glucose ranges (time in the range 70–180 mg/dL) and time spent above and below the target. Late last year, the FDA held a meeting in Washington, DC where the discussion was about moving beyond A1c.16 We hope the future will see time in range, above target range, and below target range as important tools to quantify glucose control like A1c on a day-to-day basis. Since A1c gives only a snapshot of overall glucose control, a new composite metric for the assessment of glucose control based on CGM data is explained by Hirsch et al. in this supplement. Another advantage of CGM use is alerts and alarms where subjects can be alarmed for impending hypoglycemia and hyperglycemia based on the rate of change of glucose, and thus patients can act accordingly. Using CGM may have great

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/dia.2017.0097

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Garg, S. K., & Akturk, H. K.
Venue
Diabetes Technology & Therapeutics
Published
2017-06
Volume
19
Issue
S3
Pages
S-1-S-2
ISSN
  • 1520-9156 (ISSN-L)
  • 1557-8593
OpenAlex
W2055963248
Cited by
34
References
9
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.